enalkiren has been researched along with losartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foote, EF; Halstenson, CE | 1 |
| Anderson, P; Bolger, G; Jaramillo, J; Jung, G; Lamarre, D; Liard, F; Pilote, L; Simoneau, B; Thibeault, D; Vigeant, JC | 1 |
1 review(s) available for enalkiren and losartan
| Article | Year |
|---|---|
New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Dipeptides; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Renin; Tetrazoles | 1993 |
1 other study(ies) available for enalkiren and losartan
| Article | Year |
|---|---|
The human renin infused rat: use as an in vivo model for the biological evaluation of human renin inhibitors.
Topics: Administration, Oral; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Dipeptides; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ganglionic Blockers; Humans; In Vitro Techniques; Losartan; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Renin; Time Factors | 1999 |